التفاصيل البيبلوغرافية
| العنوان: |
Use of antihistamines for COVID-19 vaccine recipients with risk of anaphylaxis. |
| المؤلفون: |
Grabowski, Jakub, Wolff, Monika, Pettersson, Samuel D, Brancewicz, Tomasz, Bidzan, Leszek |
| المصدر: |
European Journal of Translational & Clinical Medicine; 2022, Vol. 5 Issue 1, p8-11, 4p |
| مصطلحات موضوعية: |
ANAPHYLAXIS, COVID-19 vaccines, ANTIHISTAMINES, ALLERGY diagnosis, COVID-19 pandemic |
| مستخلص: |
Allergic reactions to COVID-19 vaccine ranging from mild to severe have been reported in patients with a history of anaphylaxis. Currently, no guidelines are available regarding prevention of allergic reactions in patients with high-risk of anaphylaxis who plan on receiving the SARS-CoV-2 vaccine. In this case-series study, two patients with a history of anaphylaxis had taken antihistaminic drugs prior to their BNT162b2 vaccinations and experienced no major allergic reactions afterwards. The use of antihistamines prior to COVID-19 vaccination may have affected the outcome of the two subjects with history of anaphylaxis history. However, further studies are needed to evaluate efficacy, generalizability and safety of the approach presented in this case-series. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Translational & Clinical Medicine is the property of Medical University of Gdansk and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
